Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9517071 | 0.79 | NPC1 (0.33) | MAPTALDH1A1 | |
| SCHEMBL11473166 | 0.78 | SLC2A1 (0.45) | MAPTALDH1A1 | |
| SCHEMBL11473169 | 0.78 | SLC2A1 (0.45) | MAPTALDH1A1 | |
| SCHEMBL12441774 | 0.74 | MAPT (0.35) | MAPTALDH1A1 | |
| SCHEMBL29793430 | 0.74 | ALDH1A1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL1187005 | 0.72 | — | — | |
| SCHEMBL11087844 | 0.72 | — | — | |
| SCHEMBL11839998 | 0.71 | GLO1 (0.35) | ALDH1A1 | |
| SCHEMBL11839992 | 0.71 | GLO1 (0.35) | ALDH1A1 | |
| SCHEMBL11825958 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-9643979-B2 | Inhibitors of DNA gyrase for the treatment of bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2015-10-08 | — | — | US | disclosed |
| EP-2906216-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vitas Pharma Research Private Limited (IN) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057415-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PVT LTD (IN) | 2014-04-17 | — | — | WO | disclosed |
| EP-0430001-B1 | Process for preparing benzaldehydes | BAYER AG (DE) | 1993-12-22 | — | — | EP | disclosed |
| US-5082976-A | PROCESS FOR THE PREPARATION OF BENZALDEHYDES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-01-21 | — | — | US | disclosed |
| EP-0430001-A1 | Process for preparing benzaldehydes | BAYER AG (DE) | 1991-06-05 | — | — | EP | disclosed |
| EP-0131043-A1 | PROCESS FOR PRODUCING POLYNUCLEOTIDES | Board of Trustees of Southern Illinois University (US) | 1985-01-16 | — | — | EP | disclosed |
| WO-1984002526-A1 | PROCESS FOR PRODUCING POLYNUCLEOTIDES | UNIV SOUTHERN ILLINOIS (US) | 1984-07-05 | — | — | WO | disclosed |
| US-4267349-A | Process for the preparation of 2-substituted-alkyl-1-alkyl-nitroimidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4232165-A | 2-Substituted-1-alkyl-nitroimidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1980-11-04 | — | — | US | disclosed |
| US-4218460-A | NITROIMIDAZOLYLVINYLTHIADIAZOLES; TREATMENT OF TRICHOMONIASIS, TRYPANOSOMIASIS, AMOEBIC DYSENTERY | BASF AKTIENGESELLSCHAFT (DE) | 1980-08-19 | — | — | US | disclosed |
| EP-0006463-A1 | Process for the production of 2-substituted 1-alkyl-nitroimidazoles | BASF Aktiengesellschaft (DE) | 1980-01-09 | — | — | EP | disclosed |
| US-4080340-A | Nitroimidazoles | MERCK & CO., INC. (US) | 1978-03-21 | — | — | US | disclosed |
| US-4010176-A | Isoxazole substituted nitroimidazoles | MERCK & CO., INC. (US) | 1977-03-01 | — | — | US | disclosed |
| US-3973019-A | Pharmaceutical compositions containing 1,4-bis-(5'-nitroimidazolyl-2'-methylene-imino) piperazine compounds for treating protozoal diseases and methods for treating such diseases | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
| US-3973019-A | Pharmaceutical compositions containing 1,4-bis-(5'-nitroimidazolyl-2'-methylene-imino) piperazine compounds for treating protozoal diseases and methods for treating such diseases | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
| US-3960882-A | IMIDAZOLYLPROPENOIC ACID ESTER | MONTANARI ROBERTO | 1976-06-01 | — | — | US | disclosed |
| US-3903081-A | 1,4-Bis-(5{40 -nitroimidazolyl-2{40 -methylene-imino)-piperazines | HOECHST AG | 1975-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | MAPT 3965/4885ALDH1A1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.